Reports
Sale
Global Narcolepsy Drugs Market Share, Size, Trends, Forecast: By Drug Class: Selective Histamine H3-Receptor Antagonist, Stimulants, Others; By Disease Type; By Dosage Form; By Route of Administration; By Population Type; By End User; By Treatment Channel; By Distribution Channel; Regional Analysis; Supplier Landscape; 2024-2032
Global Narcolepsy Drugs Market Outlook
The global narcolepsy drugs market reached a value of nearly USD 3.63 billion in 2023 and is further projected to achieve USD 8.85 billion by 2032, recording a CAGR of 10.4% over the forecast period of 2024-2032.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The industry is being driven by the rapidly advancing technology, increased investment in the R&D sector by leading pharmaceutical companies, and the rising awareness regarding narcolepsy and its treatment among people.
Market Segmentation
Narcolepsy refers to a sleep disorder that causes excessive daytime drowsiness and is characterised by sleep paralysis and hallucinations, among other factors. It is a neurological disorder involving a reduced capacity to control sleep and wake cycles. The global narcolepsy drugs market can be segmented into disease type and therapeutic type.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The industry can be divided based on its disease types into daytime extreme sleepiness and cataplexia, among others. The industry is broadly categorised based on its therapeutic types into:
- Central Nervous System Stimulants
- Tricyclic Antidepressants
- Sodium Oxybate
- Selective Serotonin Reuptake Inhibitor
- Others
The EMR report looks into the regional narcolepsy drugs markets like North America, Latin America, the Asia Pacific, Europe, and the Middle East and Africa.
Market Analysis
The increased prevalence of narcolepsy, awareness regarding sleep disorders due to narcolepsy awareness programmes and camps, and the growing presence of reimbursement policies are the major factors that are accelerating the growth of the global narcolepsy drugs market. Further, the rising disposable incomes and increased expenditure in the health care sector by the governments, particularly in the developing nations, is expected to aid the global narcolepsy drugs market over the forecast period. The adverse effects related to narcolepsy drugs, along with the chances of delayed diagnosis or misdiagnosis, are the major drawbacks, which may affect the industry growth in the forecast period.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Competitive Landscape
The report presents a detailed analysis of the following key players in the global narcolepsy drugs market, looking into their capacity, market shares, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:
- Arena Pharmaceutical, Inc.
- Jazz Pharmaceutical Plc
- Bioprojet Pharma Sarl
- Ligand Pharmaceuticals Incorporated
- Shinogi Inc.
- Takeda Pharmaceutical Company
- Teva Pharmaceutical Industries Ltd.
- Others
The EMR report gives an in-depth insight into the industry by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Drug Class |
|
| Breakup by Disease Type |
|
| Breakup by Dosage Form |
|
| Breakup by Route of Administration |
|
| Breakup by Population Type |
|
| Breakup by End User |
|
| Breakup by Treatment Channel |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
| Report Price and Purchase Option | Explore our purchase options that are best suited to your resources and industry needs. |
| Delivery Format | Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option. |
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Narcolepsy Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Narcolepsy Epidemiology Analysis
5.1 Epidemiology Overview (2016-2031)
5.2 North America Narcolepsy Epidemiology (2016-2031)
5.3 Europe Narcolepsy Epidemiology (2016-2031)
5.4 Asia-Pacific Narcolepsy Epidemiology (2016-2031)
5.5 Latin America Narcolepsy Epidemiology (2016-2031)
5.6 Middle East & Africa Narcolepsy Epidemiology (2016-2031)
6 Global Narcolepsy Drugs Market Overview
6.1 Global Narcolepsy Drugs Market Historical Value (2017-2023)
6.2 Global Narcolepsy Drugs Market Forecast Value (2024-2032)
7 Global Narcolepsy Drugs Market Landscape
7.1 Global Narcolepsy Drugs: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Global Narcolepsy Drugs Product Landscape
7.2.1 Analysis by Therapeutic Class
7.2.2 Analysis by Diseases Type
7.2.3 Analysis by Population Type
7.2.4 Analysis by End User
8 Narcolepsy Treatment Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Global Narcolepsy Drugs Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Global Narcolepsy Drugs Market Segmentation
11.1 Global Narcolepsy Drugs Market by Drug Class
11.1.1 Market Overview
11.1.2 Selective Histamine H3-Receptor Antagonist
11.1.3 Stimulants
11.1.4 Serotonin Reuptake Inhibitors (SSRIs)
11.1.5 Tricyclic Antidepressants
11.1.6 Central Nervous System Depressant
11.1.7 Others
11.2 Global Narcolepsy Drugs Market by Disease Type
11.2.1 Market Overview
11.2.2 Narcolepsy with Cataplexy
11.2.3 Narcolepsy without Cataplexy
11.2.4 Secondary Narcolepsy
11.3 Global Narcolepsy Drugs Market by Dosage Form
11.3.1 Market Overview
11.3.2 Tablet
11.3.3 Capsule
11.3.4 Injectables
11.3.5 Others
11.4 Global Narcolepsy Drugs Market by Route of Administration
11.4.1 Market Overview
11.4.2 Oral
11.4.3 Parenteral
11.5 Global Narcolepsy Drugs Market by Population Type
11.5.1 Market Overview
11.5.2 Childrens
11.5.3 Adults
11.5.4 Geriatrics
11.6 Global Narcolepsy Drugs Market by End User
11.6.1 Market Overview
11.6.2 Hospitals
11.6.3 Specialty Clinics
11.6.4 Homecare
11.6.5 Others
11.7 Global Narcolepsy Drugs Market by Treatment Channel
11.7.1 Market Overview
11.7.2 Public
11.7.3 Private
11.8 Global Narcolepsy Drugs Market by Distribution Channel
11.8.1 Market Overview
11.8.2 Hospital Pharmacy
11.8.3 Online Pharmacy
11.8.4 Retail Pharmacy
11.9 Global Narcolepsy Drugs Market by Region
11.9.1 Market Overview
11.9.2 North America
11.9.3 Europe
11.9.4 Asia Pacific
11.9.5 Latin America
11.9.6 Middle East and Africa
12 North America Narcolepsy Drugs Market
12.1 Market Share by Country
12.2 United States of America
12.3 Canada
13 Europe Narcolepsy Drugs Market
13.1 Market Share by Country
13.2 United Kingdom
13.3 Germany
13.4 France
13.5 Italy
13.6 Others
14 Asia Pacific Narcolepsy Drugs Market
14.1 Market Share by Country
14.2 China
14.3 Japan
14.4 India
14.5 ASEAN
14.6 Australia
14.7 Others
15 Latin America Narcolepsy Drugs Market
15.1 Market Share by Country
15.2 Brazil
15.3 Argentina
15.4 Mexico
15.5 Others
16 Middle East and Africa Narcolepsy Drugs Market
16.1 Market Share by Country
16.2 Saudi Arabia
16.3 United Arab Emirates
16.4 Nigeria
16.5 South Africa
16.6 Others
17 Regulatory Framework
17.1 Regulatory Overview
17.1.1 US FDA
17.1.2 EU EMA
17.1.3 INDIA CDSCO
17.1.4 JAPAN PMDA
17.1.5 Others
18 Patent Analysis
18.1 Analysis by Type of Patent
18.2 Analysis by Publication year
18.3 Analysis by Issuing Authority
18.4 Analysis by Patent Age
18.5 Analysis by CPC Analysis
18.6 Analysis by Patent Valuation
18.7 Analysis by Key Players
19 Grants Analysis
19.1 Analysis by year
19.2 Analysis by Amount Awarded
19.3 Analysis by Issuing Authority
19.4 Analysis by Grant Application
19.5 Analysis by Funding Institute
19.6 Analysis by NIH Departments
19.7 Analysis by Recipient Organization
20 Clinical Trials Analysis
20.1 Analysis by Trial Registration Year
20.2 Analysis by Trial Status
20.3 Analysis by Trial Phase
20.4 Analysis by Therapeutic Area
20.5 Analysis by Geography
21 Funding and Investment Analysis
21.1 Analysis by Funding Instances
21.2 Analysis by Type of Funding
21.3 Analysis by Funding Amount
21.4 Analysis by Leading Players
21.5 Analysis by Leading Investors
21.6 Analysis by Geography
22 Partnership and Collaborations Analysis
22.1 Analysis by Partnership Instances
22.2 Analysis by Type of Partnership
22.3 Analysis by Leading Players
22.4 Analysis by Geography
23 Supplier Landscape
23.1 Avadell
23.1.1 Financial Analysis
23.1.2 Product Portfolio
23.1.3 Demographic Reach and Achievements
23.1.4 Mergers and Acquisitions
23.1.5 Certifications
23.2 Vallon Pharmaceuticals
23.2.1 Financial Analysis
23.2.2 Product Portfolio
23.2.3 Demographic Reach and Achievements
23.2.4 Mergers and Acquisitions
23.2.5 Certifications
23.3 Jazz Pharmaceuticals, Inc.
23.3.1 Financial Analysis
23.3.2 Product Portfolio
23.3.3 Demographic Reach and Achievements
23.3.4 Mergers and Acquisitions
23.3.5 Certifications
23.4 Jubilant Pharmova Limited
23.4.1 Financial Analysis
23.4.2 Product Portfolio
23.4.3 Demographic Reach and Achievements
23.4.4 Mergers and Acquisitions
23.4.5 Certifications
23.5 BIOPROJET
23.5.1 Financial Analysis
23.5.2 Product Portfolio
23.5.3 Demographic Reach and Achievements
23.5.4 Mergers and Acquisitions
23.5.5 Certifications
23.6 Hikma Pharmaceuticals PLC
23.6.1 Financial Analysis
23.6.2 Product Portfolio
23.6.3 Demographic Reach and Achievements
23.6.4 Mergers and Acquisitions
23.6.5 Certifications
23.7 Amneal Pharmaceuticals LLC
23.7.1 Financial Analysis
23.7.2 Product Portfolio
23.7.3 Demographic Reach and Achievements
23.7.4 Mergers and Acquisitions
23.7.5 Certifications
23.8 Teva Pharmaceutical Industries Ltd.
23.8.1 Financial Analysis
23.8.2 Product Portfolio
23.8.3 Demographic Reach and Achievements
23.8.4 Mergers and Acquisitions
23.8.5 Certifications
23.9 Ligand Pharmaceuticals Incorporated
23.9.1 Financial Analysis
23.9.2 Product Portfolio
23.9.3 Demographic Reach and Achievements
23.9.4 Mergers and Acquisitions
23.9.5 Certifications
23.10 Novartis AG
23.10.1 Financial Analysis
23.10.2 Product Portfolio
23.10.3 Demographic Reach and Achievements
23.10.4 Mergers and Acquisitions
23.10.5 Certifications
23.11 Mylan N.V.
23.11.1 Financial Analysis
23.11.2 Product Portfolio
23.11.3 Demographic Reach and Achievements
23.11.4 Mergers and Acquisitions
23.11.5 Certifications
23.12 Alkem Labs
23.12.1 Financial Analysis
23.12.2 Product Portfolio
23.12.3 Demographic Reach and Achievements
23.12.4 Mergers and Acquisitions
23.12.5 Certifications
23.13 Alembic Pharmaceuticals Limited
23.13.1 Financial Analysis
23.13.2 Product Portfolio
23.13.3 Demographic Reach and Achievements
23.13.4 Mergers and Acquisitions
23.13.5 Certifications
23.14 Torrent Pharmaceuticals Ltd.
23.14.1 Financial Analysis
23.14.2 Product Portfolio
23.14.3 Demographic Reach and Achievements
23.14.4 Mergers and Acquisitions
23.14.5 Certifications
23.15 Johnson & Johnson
23.15.1 Financial Analysis
23.15.2 Product Portfolio
23.15.3 Demographic Reach and Achievements
23.15.4 Mergers and Acquisitions
23.15.5 Certifications
23.16 F. Hoffmann-La Roche Ltd.
23.16.1 Financial Analysis
23.16.2 Product Portfolio
23.16.3 Demographic Reach and Achievements
23.16.4 Mergers and Acquisitions
23.16.5 Certifications
23.17 Zydus Cadila
23.17.1 Financial Analysis
23.17.2 Product Portfolio
23.17.3 Demographic Reach and Achievements
23.17.4 Mergers and Acquisitions
23.17.5 Certifications
24 Narcolepsy Drugs Market- Distribution Model (Additional Insight)
24.1 Overview
24.2 Potential Distributors
24.3 Key Parameters for Distribution Partner Assessment
25 Key Opinion Leaders (KOL) Insights (Additional Insight)
26 Company Competitiveness Analysis (Additional Insight)
26.1 Very Small Companies
26.2 Small Companies
26.3 Mid-Sized Companies
26.4 Large Companies
26.5 Very Large Companies
27 Payment Methods (Additional Insight)
27.1 Government Funded
27.2 Private Insurance
27.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
In 2020, the global narcolepsy drugs market attained a value of about USD 3.63 billion in 2023.
The market is projected to grow at a CAGR of 10.4% between 2024 and 2032.
The market is being driven by the rising awareness regarding narcolepsy and its treatment methods, technological advancements, and the increasing research and development (R&D) activities.
The market growth is anticipated to be defined by the rising disposable incomes, the increasing expenditure in the healthcare sector, and the introduction of favourable governmental initiatives to enhance the accessibility of narcolepsy drugs.
The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
The major disease types of narcolepsy drugs include daytime extreme sleepiness and cataplexia, among others.
The significant therapeutic types of narcolepsy drugs are central nervous system stimulants, tricyclic antidepressants, sodium oxybate, and selective serotonin reuptake inhibitor, among others.
The major players in the industry are Arena Pharmaceutical, Inc., Jazz Pharmaceutical Plc, Bioprojet Pharma Sarl, Ligand Pharmaceuticals Incorporated, Shinogi Inc., Takeda Pharmaceutical Company, and Teva Pharmaceutical Industries Ltd., among others.
Analyst Review
The global narcolepsy drugs market attained a value of nearly USD 3.63 billion in 2023, driven by the rising awareness regarding narcolepsy. Aided by the introduction of various favourable governments initiatives, the market is expected to witness a further growth in the forecast period of 2024-2032, growing at a CAGR of 10.4%.
EMR’s meticulous research methodology delves deep into the market, covering the macro and micro aspects of the industry. Based on disease type, the narcolepsy drugs industry can be divided into daytime extreme sleepiness and cataplexia, among others. On the basis of therapeutic type, the market can be classified into central nervous system stimulants, tricyclic antidepressants, sodium oxybate, and selective serotonin reuptake inhibitor, among others. The major regional markets for narcolepsy drugs are North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. The key players in the above market include Arena Pharmaceutical, Inc., Jazz Pharmaceutical Plc, Bioprojet Pharma Sarl, Ligand Pharmaceuticals Incorporated, Shinogi Inc., Takeda Pharmaceutical Company, and Teva Pharmaceutical Industries Ltd., among others.
EMR’s research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable, and help them remain ahead of their competition.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 2969
$2699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 5499
$4999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 6599
$5999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 7699
$6999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER